Cargando…

Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review

INTRODUCTION: The introduction of immuno-oncology (IO) therapies has changed the treatment landscape of non-small cell lung cancer (NSCLC). Numerous cost-effectiveness analyses (CEAs) and technology appraisals (TAs) evaluating IO therapies have been recently published. OBJECTIVE: We reviewed economi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kongnakorn, Thitima, Sarri, Grammati, Freitag, Andreas, Marczell, Kinga, Kazmierska, Paulina, Masters, Elizabeth, Pawar, Vivek, Zhang, Xinke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795065/ https://www.ncbi.nlm.nih.gov/pubmed/34595671 http://dx.doi.org/10.1007/s40273-021-01089-4

Ejemplares similares

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
por: Kongnakorn, Thitima, et al.
Publicado: (2014)

Global prevalence of long-term neurodevelopmental impairment following extremely preterm birth: a systematic literature review
por: Sarda, Sujata P., et al.
Publicado: (2021)

Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations
por: Freitag, Andreas, et al.
Publicado: (2023)

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
por: Najafi, Masoumeh, et al.
Publicado: (2023)

Statistical issues and challenges in immuno-oncology
por: Chen, Tai-Tsang
Publicado: (2013)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
por: Ji, Yan, et al.
Publicado: (2018)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Author Correction: The immuno-oncological challenge of COVID-19
por: Derosa, Lisa, et al.
Publicado: (2022)

Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How
por: Sarri, Grammati
Publicado: (2022)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Identification of continued challenges and opportunities in oncologists' comprehension of immuno-oncology
por: Herrmann, Tara, et al.
Publicado: (2015)

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
por: Sancho-Araiz, Aymara, et al.
Publicado: (2021)

Challenges associated with the integration of immuno-oncology agents in clinical practice
por: Lazure, Patrice, et al.
Publicado: (2022)

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements
por: Muir, Jeffrey M., et al.
Publicado: (2023)

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
por: Nadler, Eric, et al.
Publicado: (2020)

Cost-effectiveness of atrial fibrillation screening in Canadian community practice
por: Andrade, Jason G., et al.
Publicado: (2022)

Current clinical challenges and opportunities in oncologists' familiarity and understanding of immuno-oncology
por: Herrmann, Tara, et al.
Publicado: (2014)

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

Immune contexture analysis in immuno‐oncology: applications and challenges of multiplex fluorescent immunohistochemistry
por: Shakya, Reshma, et al.
Publicado: (2020)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Immuno-oncology for B-cell lymphomas
por: Choi, Yoon Seok
Publicado: (2021)

Virus-Based Immuno-Oncology Models
por: Sitta, Juliana, et al.
Publicado: (2022)

Organoids as an Enabler of Precision Immuno-Oncology
por: Zhao, Junzhe, et al.
Publicado: (2023)

Single-Cell Analysis in Immuno-Oncology
por: Christodoulou, Maria-Ioanna, et al.
Publicado: (2023)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

Racing CARs to veterinary immuno-oncology
por: Cockey, James R., et al.
Publicado: (2023)

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
por: Rivolo, Simone, et al.
Publicado: (2021)

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
por: Sheng, Lei, et al.
Publicado: (2021)

Immuno-Oncology: Emerging Targets and Combination Therapies
por: Marshall, Henry T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hm39q8g1b2rqfi9t7f2uosorcm